Peerview Gastroenterology Cme/cne/cpe Audio Podcast

Go online to PeerView.com/WNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As the treatment landscape for gastric and gastroesophageal junction (GEJ) cancers continues to evolve, patients with these heterogenous and aggressive malignancies are benefiting from improved outcomes. Targeted therapies, such as anti-angiogenic agents, have had a beneficial role in the second-line gastric and GEJ cancer settings after prior fluoropyrimidine- or platinum-containing chemotherapy, while novel combinations with anti-angiogenesis agents, chemotherapy, and/or immunotherapy are showing promise in clinical trials. Furthermore, first-line therapy with an immune checkpoint inhibitor in combination with chemotherapy recently demonstrated improved outcomes over chemotherapy alone, and these data led to an FDA approval that is ushering in a new immunotherapy-based standard of care in the frontline treatment of newly diagnosed gastric and GEJ cancers. Join PeerView for an